TITLE

Tamoxifen, SSRIs, and Breast Cancer Recurrence

AUTHOR(S)
Elliott, William T.
PUB. DATE
September 2009
SOURCE
Internal Medicine Alert;9/16/2009 Clinical Briefs, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article offers news briefs related to pharmacology in the U.S. The prasugrel, an oral antiplatelet agent use in preventing thrombosis in patients with acute coronary syndrome, has been approved by the Food and Drug Administration (FDA). The FDA is focusing its attention on the propoxyphene-containing pain medications including Darvon and Darvocet due to data that links propoxyphene to fatal overdoses. The interim safety findings of omalizumab is evaluated by the FDA.
ACCESSION #
44254687

 

Related Articles

  • Pradaxa not linked to excess bleeding risk.  // Hem/Onc Today;12/10/2012, Vol. 13 Issue 23, p9 

    The article reports on the drug safety communication issued by the U.S. Food and Drug Administration (FDA) concerning the bleeding rates associated with the anticoagulant medication dabigatran.

  • Propoxyphene and Overdose Risk. Elliott, William T. // Primary Care Reports;Sep2009 Supplement, p2 

    The article reports that a new box warning is being ordered by the Food and Drug Administration (FDA) in the U.S. for pain mediations, such as Darvon® and Darvocet®, containing propoxyphene. The FDA found that there are data connecting death an overdose of propoxyphene. On the other hand,...

  • Propoxyphene and Overdose Risk. Elliott, William T. // Clinical Oncology Alert;Sep2009 Supplement, p2 

    The article reports that a new box warning for propoxyphene-containing pain medications such as Darvon® and Darvocet® has been ordered by the Food and Drug Administration (FDA) in the U.S. The agency required such warning because of potential overdose. On the other hand, the request by...

  • FDA Acts on Painkiller Risk.  // Chain Drug Review;7/20/2009, Vol. 31 Issue 12, p119 

    The article reports on the move of U.S. Food and Drug Administration (FDA) to reduce the risk of overdose in patients are taking pain medications that have propoxyphene. The FDA has ordered drug manufacturers to strengthen the label of products that contain propoxyphene including the boxed...

  • FDA: Pradaxa not linked to excess bleeding risk.  // Cardiology Today;Dec2012, Vol. 15 Issue 12, p38 

    The article deals with a drug safety communication issued by the U.S. Food and Drug Administration (FDA) which indicated that bleeding rates associated with dabigatran seemed not to be higher than those associated with warfarin.

  • Managing risks of dabigatran.  // Reactions Weekly;Aug2014, Vol. 1514 Issue 1, p2 

    The article discusses a study conducted by Thomas J. Moore and colleagues about the efficacy and safety of dabigatran etexilate in the prevention of stroke in patients with nonvalvular atrial fibrillation (AF). It argues that the European Medicines Agency (EMA) and the U.S. Food and Drug...

  • FDA REVIEWS GUIDANCE STATUS.  // Pharmaceutical Technology;Oct2013, Vol. 37 Issue 10, p40 

    The article offers information on the revised status of the draft guidance documents related to drug products reviewed by the Center for Dug Evaluation and Research (CDER), a division of the U.S. Food and Drug Administration. It informs that the CDER has identified 23 draft guidances for...

  • Getting the Scoop on Your Drugs. Fields, Helen; Mcgrath, Anne // U.S. News & World Report;11/28/2005, Vol. 139 Issue 20, p76 

    The article discusses warnings about prescription drugs. A study published in the journal "Pharmacoepidemicology and Drug Safety" found that doctors frequently don't heed the drug makers' guidance. In many cases, rushed doctors undoubtedly miss warnings required by the U.S. Food & Drug...

  • Eyes on New Product Development. Novack, Gary D. // Journal of Ocular Pharmacology & Therapeutics;Nov2014, Vol. 30 Issue 9, p687 

    The article presents 2014 news on ocular pharmacology and therapeutics. The U.S. Food and Drug Administration has given approval to the company Regeneron Pharmaceuticals Inc. for the drug Eylea. The drug firm Roche Pharmaceuticals Ltd. is beginning clinical trials on the drug lampalizumab for...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics